Project Grant R01CA293596
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$664K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This $570,096 Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) supports research by Northwestern University to investigate how the epigenetic regulator EZH2 impacts RNA modifications, particularly N6-methyladenosine (m6A), in the progression of advanced prostate cancer. The project aims to precisely identify the non-canonical role of EZH2 in regulating m6A levels, as the researchers have found that dysregulation of EZH2 alters m6A, leading to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $582,198 to Northwestern University from Jul 12, 2024 to Jun 30, 2029 to conduct research on the role of the EZH2 protein in regulating PARP1 function and PARP inhibitor resistance in prostate cancer. The research aims to identify how EZH2-mediated PARP1 methylation impacts DNA damage repair and transcription activity, with the goal of developing new EZH2 and PARP1...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $563,663 to the University of Southern California (USC) to identify small molecule inhibitors targeting the Polycomb Repressive Complexes 1 and 2 (PRC1 and PRC2). The overarching goal is to develop mechanistic insights and potential therapeutic approaches for treating EZH2-dependent cancers, which are only partially responsive to existing EZH2 catalytic inhibitors. The project...
The federal Project Grant award titled "TOWARDS CHARACTERIZATION OF EPIGENETIC TARGETS IN PROSTATE CANCER" is funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The $371,719 award, spanning March 1, 2025 to February 28, 2030, will support research conducted by The Trustees of the University of Pennsylvania to gain deeper molecular insights into how the epigenetic regulator NSD2 influences the chromatin landscape and AR...
This $1,631,656 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unveil the role of the UBE2J1 protein as the E2 ubiquitin conjugating enzyme regulating androgen receptor (AR) degradation in prostate cancer. The research aims to comprehensively analyze how UBE2J1 governs AR functions, elucidate the molecular mechanisms of UBE2J1-mediated AR degradation, and evaluate the effectiveness of using...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in the amount of $849,371 on August 2, 2024. The grant, titled "Hijacking Post-Translational Arginylation for Targeted Protein Degradation," aims to develop innovative methods for targeted protein degradation using the arginylation pathway. Key project activities include: 1) Applying computational techniques to identify potential ATE1 binding compounds,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $653,897 in funding to the University of Virginia to develop and evaluate novel small molecule inhibitors of the transcription factor ERG as a new approach for treating prostate cancer. The key objectives are to optimize the inhibitors for potency and specificity (Aim 1) and conduct preclinical evaluation in prostate cancer cell lines, patient tissue models, and patient-derived...
The National Cancer Institute (CFDA 93.396 Cancer Biology Research) awarded a $218,886 Project Grant to The Trustees of Columbia University in the City of New York to develop a novel technology for targeted protein degradation in cancer cells. The key products and services to be delivered under this 3-year award, which began on January 2, 2025, include: Optimizing a light-activated catalytic system to efficiently cleave and degrade specific cancer-related proteins, including the immune...
The National Cancer Institute (NCI) awarded a $393,401 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Washington State University (WSU) to develop a PSMA-targeted small-molecule dual drug conjugate (SMDDC) for treating metastatic castration-resistant prostate cancer (mCRPC) and other PSMA-positive malignancies. The project aims to assess the spatio-temporal cargo release of a PSMA-targeted SMDPC and determine the potency enhancement of a SMDDC bearing dual chemotherapeutic payloads...
This $472,458 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to examine the role of the protein tyrosine phosphatase PTPN1 in driving therapy- and castration-resistant prostate cancer (T-CRPC) and the development of neuroendocrine prostate cancer (NEPC). The key objectives are to: 1) Investigate the regulation of PTPN1 gene expression by anti-androgen therapies and the reciprocal relationship between PTPN1, the androgen...